How should we treat major depression combined with anxiety? by Trotter, Bonnie et al.
306	 vol 56, No 4 / april 2007  The Journal of family PracTice
CliniCal iNquiries From the Family Physicians 
Inquiries Network
How	should	we	treat		
major	depression		
combined	with	anxiety?
Bonnie Trotter, MD, MPH, 
Gary Kelsberg, MD
Valley Family Medicine  
Residency, Renton, Wash
leilani St. anna, MliS, aHiP
University of Washington Health 
Sciences Libraries, Seattle
evidence-based answer
one approach is to use antidepressants 
alone, which reduce symptoms for patients 
with major depression plus symptoms of 
anxiety or major depression plus generalized 
anxiety disorder. selective serotonin 
reuptake inhibitors (ssris), tricyclics (TCas), 
bupropion, mirtazapine, nefazodone, 
and venlafaxine are equally effective for 
combined symptom relief (strength of 
recommendation [sor]: a, based on 
systematic review of randomized controlled 
trials [rCTs]).
 another approach is to add a 
benzodiazepine to the antidepressant.  
This reduces anxiety symptoms (more in the 
short term) and decreases patient dropout, 
but it also has possible harms, including 
development of dependence and accident 
proneness (sor: a, based on systematic 
review of rCTs).
 psychotherapy, particularly cognitive 
behavioral therapy, produces and maintains 
reductions in symptoms of anxiety and 
depression that are  comparable with the 
reductions seen with medication (sor: a, 
based on systematic review of rCTs).
clinical commentary
Talk to the patient about risks and benefits 
of drug therapy, and the need to closely 
monitor him in the first few weeks
such discussions are essential, in light 
of the Food and Drug administration’s 
mandate that all classes of antidepressant 
carry a black box warning label about 
increased suicidality (suicidal thinking and 
behavior) among patients taking these 
medications.1
 Benzodiazepine medications are 
effective in mitigating symptoms of anxiety 
but have additional risks such as altered 
cognition, tolerance, and abuse potential. 
in addition, benzodiazepine can be lethal 
in overdose with alcohol. Therefore, using 
a benzodiazepine alone for a patient who 
has both anxiety and depression is unwise. 
even when used in combination with an 
antidepressant, benzodiazepine therapy 
should be brief.
Vincent lo, MD
san Joaquin Family Medicine residency, French 
Camp, Calif
z	Evidence	summary
Antidepressants	have	similar		
positive	effects
A systematic review of 28 randomized 
trials comparing various antidepressant 
medications found no significant differ-
ences in reduction of symptoms of de-
pression and anxiety for patients who 
had both.2 Patients in these trials met 
DSM (Diagnostic and Statistical Man-
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ual of Mental Health) criteria for major 
depression, with symptom severity as 
measured by a standardized scale, the 
Hamilton Rating Scale for Depression 
(HAM-D). They also had moderate to se-
vere levels of anxiety symptoms as mea-
sured by standardized scales (Hamilton 
Rating Scale for Anxiety [HAM-A], Covi 
Anxiety Rating Scale, or the anxiety/ 
somatization factors on the HAM-D). 
Trials ranged from 6 to 24 weeks 
long, with outcomes including reductions 
in depression and anxiety symptom scores 
as measured by standardized scales. Study 
quality was variable; only 8 trials used a 
placebo control, and many were spon-
sored by pharmaceutical manufacturers. 
Although some individual studies 
found differences in outcomes between 
medications, no significant differences in 
efficacy were seen in combined data from 
each comparison group. Medication was 
more efficacious than placebo in most 
studies that used a placebo control. Side-
effect profiles were not described. 
Patients with major depression and 
high anxiety levels relapsed more of-
ten than those with low anxiety levels 
with discontinuation of fluoxetine com-
pared with placebo in a double-blind 
placebo-controlled parallel trial with 
596 patients.3
Three trials evaluated antidepressant 
medication for patients who met diag-
nostic criteria for both major depression 
and generalized anxiety disorder. A man-
ufacturer-sponsored RCT (N=90) found 
no differences in HAM-A or HAM-D 
score reduction among fluoxetine, venla-
faxine, and placebo (except at 12 weeks, 
when venlafaxine significantly differed 
from placebo).4 Two open-label cohort 
trials (N=153) found that fluoxetine and 
fluvoxamine (Luvox, an older SSRI) re-
duced both depression and anxiety by 
about half.5,6
Adding	benzodiazepines		
is	not	a	long-term	solution
A Cochrane systematic review (10 RCTs, 
N=731) compared antidepressants alone 
vs combinations with benzodiazepines 
for patients with major depression and 
a 35% to 85% estimated prevalence of 
anxiety symptoms. Three studies used 
standardized scales to measure anxiety 
symptom severity. 
Antidepressants in combination with 
benzodiazepines were more likely than 
antidepressants alone to reduce depres-
sion scores by 50% or more (for 50% 
depression improvement at 1 week, 
number needed to treat [NNT]=12; at 
4 weeks, NNT=8). The combination 
group also had fewer dropouts (relative 
risk [RR]=0.63, 95% confidence interval 
[CI], 0.49–0. 81). The authors concluded 
that potential benefits of adding a benzo-
diazepine to an antidepressant must be 
balanced against possible harms, such as 
the development of dependence.7
Psychotherapy	appears		
likely	to	help
A review of 13 controlled clinical 
trials8 evaluated standardized depres-
sion and anxiety score reductions for 
patients with generalized anxiety dis-
order receiving cognitive behavioral 
therapy compared with various control 
treatments (waiting list, pill placebo, or 
alternative therapy—such as supportive 
listening psychotherapy). Approximate-
ly half of the patients were also taking 
medication (not specified). 
After an average of 10 sessions, 
cognitive behavioral therapy reduced 
anxiety and depression symptom scores 
more than control treatments (differ-
ence in effect size were 0.71 and 0.66, 
respectively). At 6- to 12-month follow-
up, cognitive behavioral therapy gains 
were maintained (difference in effect 
size=0.30 for anxiety scores and 0.21 
for depression scores). (An effect size 
of 0.2 is usually considered small, 0.5 
moderate, and 0.8 is large.)
Another trial assigned primary 
care patients (N=464) with depression 
or mixed depression and anxiety to 
1 of 2 psychological therapy groups 
(cognitive behavioral therapy or non-
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directive counseling for 12 sessions) 
vs usual general practitioner care. At 
4 months, both psychological therapy 
groups had lower Beck Depression In-
dex scores (by 4–5 points) than the usu-
al general practitioner care group, but 
by 12 months there were no significant 
differences among all groups.9
Recommendations	from	others
The National Collaborating Centre for 
Mental Health guidelines state: “when 
depressive symptoms are accompanied 
by anxious symptoms, the first priority 
should usually be to treat the depression. 
Psychological treatment for depression 
often reduces anxiety, and many antide-
pressants also have sedative/anxiolytic 
effects.”10
The Brigham and Women’s Hospi-
tal guideline recommends adjunctive 
therapy with anxiolytics—such as loraz-
epam (Ativan) and clonazepam (Klono-
pin)—for some patients with depression 
and mild to moderate anxiety, to help 
control symptoms such as sleeplessness 
and restlessness.11 n
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Medicare	Update:	What	the	changes	will	mean	for	you
The big news in Medicare last year was the start of the 
prescription drug program—Medicare part D—and changes 
in physician payments beginning in January 2007. The latter 
includes revisions to the relative value unit scale, the elimination 
of the scheduled decrease in the physician fee schedule, and 
the beginnings of pay-for-performance. This article spells out 
the details of how these changes may impact your practice.  
